Sensyne Health

The company has reported robust financial performance in its 2021 unaudited revenues of at least £9.0 million compared to £2.1 million in the 2020 audited accounts.

Excalibur will integrate MagnifEye into its lateral flow products for global marketing to customers in both the public and private sectors.

Co-developed with Chelsea and Westminster Hospital, this is the first in a series of operational AI algorithms to be launched commercially and offered across the UK and US health systems.

The solution will be offered to US health systems and health plans through Cognizant, their US sales and marketing partner.